Yuhan (000100) Stock Price, Fundamentals & Analysis

What 000100 does

Yuhan (000100) is a pharmaceutical company listed on the Korea Exchange that operates in South Korea and internationally. It manufactures active pharmaceutical ingredients (APIs) and intermediates, offering custom manufacturing, process research and development, and commercial production. Its product portfolio includes antibiotics, anti-thrombotics, anti-hyperlipidemics, and anti-hypertensives, along with custom synthesis services in areas such as anti-virals, anti-HIV, anti-HCV, antihistamines, anti-diabetics, ß-lactamase inhibitors, CNS intermediates, and PEG-compounds. Founded in 1926 and headquartered in Seoul, South Korea, Yuhan operates with 2,082 employees.

Key numbers explained

• 74,100 KRW is the current price per share, representing the cost to buy one unit of the stock today.
• -1.33% is the price change today, showing the percentage move in the share price over the current trading session.
• 5.45T KRW is the market capitalization, the total value of all outstanding shares; at this size, Yuhan is a large-cap stock.
• The forward P/E ratio of 26.4 divides the current price by expected future earnings, helping investors gauge how much they pay for each unit of anticipated profit.
• The dividend yield of 0.81% shows the annual dividend payment as a percentage of the share price, indicating the cash return shareholders receive relative to the price they paid.
• 19% is the share of earnings paid out as dividends, meaning the company retains most of its profit for reinvestment.
• 0.42 is the beta, a measure of volatility relative to the market; a value below 1 suggests the stock tends to move less than the broader market.
• The 52-week range of 65,000 – 129,200 KRW shows the lowest and highest prices over the past year, while the -36.3% change over that period reflects the decline from one year ago to today.

What to watch

Investors tracking Yuhan may consider the dynamics of the drug manufacturing sector, including regulatory changes, patent expirations, and competition from peers such as Hanmi Pharm (128940), Celltrion (068270), and Chong Kun Dang (185750). The company's revenue growth of 10.4% year over year and its 10.4% profit margin are useful indicators of operational efficiency. Because Yuhan is part of the KOSPI 200, broader Korean market movements can influence its price. The upcoming ex-dividend date of Feb 26, 2026 is relevant for income-focused investors.